| Modification of sample size in group sequential clinical trials L Cui, HMJ Hung, SJ Wang Biometrics 55 (3), 853-857, 1999 | 634 | 1999 |
| The long QT syndrome. new electrocardiographic characteristics J Benhorin, M Merri, M Alberti, E Locati, A Moss, WJ Hall, L Cui Circulation 82 (2), 521-527, 1990 | 147 | 1990 |
| School problems in Tourette's syndrome DA Abwender, PG Como, R Kurlan, K Parry, KA Fett, L Cui, S Plumb, ... Archives of Neurology 53 (6), 509-511, 1996 | 111 | 1996 |
| Issues related to subgroup analysis in clinical trials L Cui, HM James Hung, SJ Wang, Y Tsong Journal of biopharmaceutical statistics 12 (3), 347-358, 2002 | 97 | 2002 |
| Group sequential test strategies for superiority and non‐inferiority hypotheses in active controlled clinical trials SJ Wang, HM James Hung, Y Tsong, L Cui Statistics in Medicine 20 (13), 1903-1912, 2001 | 79 | 2001 |
| The design of clinical trials to support the switching and alternation of biosimilars F Faccin, P Tebbey, E Alexander, X Wang, L Cui, T Albuquerque Expert Opinion on Biological Therapy 16 (12), 1445-1453, 2016 | 60 | 2016 |
| The early course of the Tourette's syndrome clinical spectrum S Park, PG Como, L Cui, R Kurlan Neurology 43 (9), 1712-1712, 1993 | 53 | 1993 |
| Statistical issues on objective, design, and analysis of noninferiority active-controlled clinical trial Y Tsong, SJ Wang, HMJ Hung, L Cui Journal of Biopharmaceutical Statistics 13 (1), 29-41, 2003 | 43 | 2003 |
| Evaluating the adaptive performance of flexible sample size designs with treatment difference in an interval GF Liu, GR Zhu, L Cui Statistics in Medicine 27 (4), 584-596, 2008 | 33 | 2008 |
| Adaptive statistical analysis following sample size modification based on interim review of effect size HM James Hung, L Cui, SJ Wang, J Lawrence Journal of Biopharmaceutical Statistics 15 (4), 693-706, 2005 | 31 | 2005 |
| The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α‐tocopherol P LeWitt, D Oakes, LU Cui, Parkinson Study Group Movement disorders 12 (2), 183-189, 1997 | 29 | 1997 |
| [Practical Markov Chain Monte Carlo]: Comment: Monitoring Convergence of the Gibbs Sampler: Further Experience with the Gibbs Stopper L Cui, MA Tanner, D Sinha, WJ Hall Statistical Science 7 (4), 483-486, 1992 | 23 | 1992 |
| A more flexible regression-to-the-mean model with possible stratification S Chen, C Cox, L Cui Biometrics, 939-947, 1998 | 16 | 1998 |
| Enrichment design with patient population augmentation B Yang, Y Zhou, L Zhang, L Cui Contemporary clinical trials 42, 60-67, 2015 | 15 | 2015 |
| Optimal adaptive group sequential design with flexible timing of sample size determination L Cui, L Zhang, B Yang Contemporary Clinical Trials 63, 8-12, 2017 | 14 | 2017 |
| Optimal flexible sample size design with robust power L Zhang, L Cui, B Yang Statistics in Medicine 35 (19), 3385-3396, 2016 | 12 | 2016 |
| Group sequential and discretized sample size re‐estimation designs: a comparison of flexibility X Wu, L Cui Statistics in Medicine 31 (24), 2844-2857, 2012 | 12 | 2012 |
| Seamless phase II/III combination study through response adaptive randomization L Wang, L Cui Journal of biopharmaceutical statistics 17 (6), 1177-1187, 2007 | 11 | 2007 |
| On the efficiency of adaptive sample size design L Cui, L Zhang Statistics in medicine 38 (6), 933-944, 2019 | 8 | 2019 |
| Levodopa drug holiday versus drug dosage reduction in Parkinson's disease R Kurlan, CM Tanner, C Goetz, J Sutton, D Lichter, P Carvey, C Deeley, ... Clinical neuropharmacology 17 (2), 117-127, 1994 | 8 | 1994 |
